← All trials
NCT07122453
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2025
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2026
- First posted
- Aug 14, 2025
- Last posted
- Aug 14, 2025
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Centrexion TherapeuticsLead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.